A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Emily J. Pomeroy; John T. Hunzeker; Mitchell G. Kluesner; Walker S. Lahr; Branden A. Smeester; Margaret R. Crosby; Cara lin Lonetree; Kenta Yamamoto; Laura Bendzick; Jeffrey S. Miller; Melissa A. Geller; Bruce Walcheck; Martin Felices; Beau R. Webber; Timothy K. Starr; Branden S. Moriarity

doi:10.1016/j.ymthe.2019.10.009

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Emily J. Pomeroy, John T. Hunzeker, Mitchell G. Kluesner, Walker S. Lahr, Branden A. Smeester, Margaret R. Crosby, Cara lin Lonetree, Kenta Yamamoto, Laura Bendzick, Jeffrey S. Miller, Melissa A. Geller, Bruce Walcheck, Martin Felices, Beau R. Webber, Timothy K. Starr, Branden S. Moriarity

Research output: Contribution to journal › Article › peer-review

93 Scopus citations

Abstract

Enhancing natural killer (NK) cell cytotoxicity could lead to improved cancer immunotherapy. In this issue of Molecular Therapy, Pomeroy et al. describe an efficient method for editing the genome of primary human NK cells using CRISPR/Cas9. The authors target genes using this method to enhance NK cell anti-tumor function.

Original language	English (US)
Pages (from-to)	52-63
Number of pages	12
Journal	Molecular Therapy
Volume	28
Issue number	1
DOIs	https://doi.org/10.1016/j.ymthe.2019.10.009
State	Published - Jan 8 2020

Bibliographical note

Funding Information:
T.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402. We acknowledge the University of Minnesota Genomics Center, the Minnesota Supercomputing Institute, and the Masonic Cancer Center for their support of this research. B.S.M. is supported by funds from NIH/NCI R21CA216652 and U54CA232561 and the Children's Cancer Research Fund. T.K.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402.

Funding Information:
T.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund , departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402 . We acknowledge the University of Minnesota Genomics Center , the Minnesota Supercomputing Institute , and the Masonic Cancer Center for their support of this research. B.S.M. is supported by funds from NIH/NCI R21CA216652 and U54CA232561 and the Children's Cancer Research Fund. T.K.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center’s Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402 .

Publisher Copyright:
© 2019 The American Society of Gene and Cell Therapy

Keywords

ADAM17
CRISPR
NK cells
PD1
immunotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.ymthe.2019.10.009

Find It

Find It at U of M Libraries

Cite this

Pomeroy, E. J., Hunzeker, J. T., Kluesner, M. G., Lahr, W. S., Smeester, B. A., Crosby, M. R., Lonetree, C. L., Yamamoto, K., Bendzick, L., Miller, J. S., Geller, M. A., Walcheck, B., Felices, M., Webber, B. R., Starr, T. K., & Moriarity, B. S. (2020). A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy, 28(1), 52-63. https://doi.org/10.1016/j.ymthe.2019.10.009

Pomeroy, EJ, Hunzeker, JT, Kluesner, MG, Lahr, WS, Smeester, BA, Crosby, MR, Lonetree, CL, Yamamoto, K, Bendzick, L , Miller, JS , Geller, MA , Walcheck, B , Felices, M , Webber, BR, Starr, TK & Moriarity, BS 2020, 'A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy', Molecular Therapy, vol. 28, no. 1, pp. 52-63. https://doi.org/10.1016/j.ymthe.2019.10.009

@article{9c8a01b11f3842bb85812cabff6519ef,

title = "A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy",

abstract = "Enhancing natural killer (NK) cell cytotoxicity could lead to improved cancer immunotherapy. In this issue of Molecular Therapy, Pomeroy et al. describe an efficient method for editing the genome of primary human NK cells using CRISPR/Cas9. The authors target genes using this method to enhance NK cell anti-tumor function.",

keywords = "ADAM17, CRISPR, NK cells, PD1, immunotherapy",

author = "Pomeroy, {Emily J.} and Hunzeker, {John T.} and Kluesner, {Mitchell G.} and Lahr, {Walker S.} and Smeester, {Branden A.} and Crosby, {Margaret R.} and Lonetree, {Cara lin} and Kenta Yamamoto and Laura Bendzick and Miller, {Jeffrey S.} and Geller, {Melissa A.} and Bruce Walcheck and Martin Felices and Webber, {Beau R.} and Starr, {Timothy K.} and Moriarity, {Branden S.}",

note = "Funding Information: T.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402. We acknowledge the University of Minnesota Genomics Center, the Minnesota Supercomputing Institute, and the Masonic Cancer Center for their support of this research. B.S.M. is supported by funds from NIH/NCI R21CA216652 and U54CA232561 and the Children's Cancer Research Fund. T.K.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402. Funding Information: T.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund , departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402 . We acknowledge the University of Minnesota Genomics Center , the Minnesota Supercomputing Institute , and the Masonic Cancer Center for their support of this research. B.S.M. is supported by funds from NIH/NCI R21CA216652 and U54CA232561 and the Children's Cancer Research Fund. T.K.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center{\textquoteright}s Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402 . Publisher Copyright: {\textcopyright} 2019 The American Society of Gene and Cell Therapy",

year = "2020",

month = jan,

day = "8",

doi = "10.1016/j.ymthe.2019.10.009",

language = "English (US)",

volume = "28",

pages = "52--63",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

AU - Pomeroy, Emily J.

AU - Hunzeker, John T.

AU - Kluesner, Mitchell G.

AU - Lahr, Walker S.

AU - Smeester, Branden A.

AU - Crosby, Margaret R.

AU - Lonetree, Cara lin

AU - Yamamoto, Kenta

AU - Bendzick, Laura

AU - Miller, Jeffrey S.

AU - Geller, Melissa A.

AU - Walcheck, Bruce

AU - Felices, Martin

AU - Webber, Beau R.

AU - Starr, Timothy K.

AU - Moriarity, Branden S.

N1 - Funding Information: T.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402. We acknowledge the University of Minnesota Genomics Center, the Minnesota Supercomputing Institute, and the Masonic Cancer Center for their support of this research. B.S.M. is supported by funds from NIH/NCI R21CA216652 and U54CA232561 and the Children's Cancer Research Fund. T.K.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402. Funding Information: T.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund , departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402 . We acknowledge the University of Minnesota Genomics Center , the Minnesota Supercomputing Institute , and the Masonic Cancer Center for their support of this research. B.S.M. is supported by funds from NIH/NCI R21CA216652 and U54CA232561 and the Children's Cancer Research Fund. T.K.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center’s Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402 . Publisher Copyright: © 2019 The American Society of Gene and Cell Therapy

PY - 2020/1/8

Y1 - 2020/1/8

N2 - Enhancing natural killer (NK) cell cytotoxicity could lead to improved cancer immunotherapy. In this issue of Molecular Therapy, Pomeroy et al. describe an efficient method for editing the genome of primary human NK cells using CRISPR/Cas9. The authors target genes using this method to enhance NK cell anti-tumor function.

AB - Enhancing natural killer (NK) cell cytotoxicity could lead to improved cancer immunotherapy. In this issue of Molecular Therapy, Pomeroy et al. describe an efficient method for editing the genome of primary human NK cells using CRISPR/Cas9. The authors target genes using this method to enhance NK cell anti-tumor function.

KW - ADAM17

KW - CRISPR

KW - NK cells

KW - PD1

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85075509964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075509964&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2019.10.009

DO - 10.1016/j.ymthe.2019.10.009

M3 - Article

C2 - 31704085

AN - SCOPUS:85075509964

SN - 1525-0016

VL - 28

SP - 52

EP - 63

JO - Molecular Therapy

JF - Molecular Therapy

IS - 1

ER -

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this